Jozefina Casuscelli

MODERN is open! Available at your site through the CRSU. Please help advance MRD-based adjuvant decision making in bladder cancer. @ALLIANCE_org @alantanmd @UroDocAsh @eaonc @SWOG @sonpavde @PaulCrispenMD @bergsa83 @SuzanneColeMD @NitinYerram @DrTylerStewart @DrRosenbergMSK

@OncBrothers @DrKarineTawagi @siadaneshmand @CancerNetwrk @BijoyTelivala @dr_yakupergun @apolo_andrea @RenoHemonc @AmandaNizamMD @PGrivasMDPhD @shilpaonc @drenriquegrande @PauloBergerot The ESMO guidlines recommends EVP as the preferred standard of care, while nivo/cis and maintenance avelumab are interchangeable and recommended when EVP is not available or contraindicated

JUST IN: @US_FDA alert: FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma! Via @ASCO @US_FDA alert ! Trial presented @myESMO #ESMO23 and published @NEJM @OncoAlert @MattGalsky @sonpavde @MichvdHeijden

EV and pembrolizumab doubling PFS and OS in 1st line UC compared to chemotherapy @NEJM

tramendous Impact German-Groups: GURDIAN and IAGN-DKG and BRIGE Network on RCC:#387,#392,#394, #478, #436; UC#553#673; Congrats to all, proud collaborating with Great Colleges! @#ASCOGU24

NECTIN4 amplification predicts response to Enfortumab vedotin in mUC! It occurs frequently across solid tumors (app. 25% of mUC)➡️potential tumor-agnostic biomarker for NECTIN4-targeting therapies! Happy to share our poster K17 @ASCO #GU24! @Markuseckstein3 @OncoAlert @urotoday

#Tweetorial: Data from Drake Lab and others shows CSPC is immunologically different and not an ‘immune desert’ like CRPC. We interrogated CSPC metastases with single-cell RNA-seq (scRNA-seq), VIPER, and IF before and after tx w/ ADT +/- aPD-1 in a Phase 2 study. /1

JUST IN and again via @ASCO #FDAAlerts The @FDAOncology approved Enfortumab Vedotin ( EV) in combo with pembrolizumab for metastatic urothelial cancer!! Data based on @tompowles1 #ESMO23 Plenary (EV-302) #StandingOvation @myESMO Great day for Bladder Cancer and our patients!

Today we announced the largest single donation in MSK’s history: $400 million – generously given by Kenneth C. Griffin, Founder and CEO of @Citadel and Founder of Griffin Catalyst, and David Geffen, Founder of The David Geffen Foundation. Learn more: bit.ly/4aaPdvn

Breaking news👉 @US_FDA approves enzalutamide with/without androgen deprivation therapy (ADT) for non-metastatic castration sensitive #ProstateCancer based on Embark trial data👇Congrats @nealshore @SFreedlandMD Link👉 t.ly/R42C6 @PCFnews @OncoAlert @urotoday

Stopping axitinib after 9 months of axititinib/avelumab in RCC shows median duration of time to progression is only 4 months off therapy #ESMO23 . That’s short and suggests it’s too early to stop? The timing of discontinuation of of therapy in RCC is a key issue. @DrIacovelli

Rechallange with pembrolizumab in UC in those patients who complete 2 yrs of therapy or stop due to CR is associated with responses. A highly selected population. What does this mean in the adjuvant therapy setting? #nashvillelive @koshkin85 #ESMO2023

Stellar presentation of ABACUS-2 data by @b_szabados: neoadjuvant Atezolizumab as option for sarcomatoid bladder cancer #ESMO23

Great Kick-off of ESMO2023 with biomarker-driven bladder cancer treatment! Local Erdafitinib potentially future standard in NMIBC, while in metastatic UC not a promising option…

The @myESMO LBAs are out And a wow for PEMBRO/EV (Presidential) OS 31.5 vs 16.1 months (HR 0.45) PFS 12.5 vs 6.3 months (HR 0.47) P<0.00001 A historic change for 1L mUC since Von Der Maase JCO 2000 @tompowles1 #ESMO23 @OncoAlert

Congratulations to our very own Dr Harry Herr on giving Department of Surgery Grand Rounds on: “Neoadjuvant Chemotherapy and Bladder Sparing Surgery for Muscle Invasive Bladder Cancer”

Great paper by Bosi et al: Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response🎯Co-expression of various ADC targets (e.g. NECTIN4) again highlights potential for agnostic ADC therapy @OncoAlert @urotoday ejcancer.com/article/S0959-…

Adjuvant pembrolizumab significance delays disease free survival in bladder cancer. The benefit is ‘clinically meaningful’ @apolo_andrea .It joins nivo, but not atezo, in having DFS. It’s not clear whether OS was tested-which is co-primary. Exciting times! merck.com/news/mercks-ke…

Neoadjuvant sasituzimab govitecan in muscle invasive bladder cancer (n=14) @Anto_cigliola @AndreaNecchi @IBCN23 Results = a mixture of efficacy (3/6 pCRs) and toxicity (TRAE G5= GCSF/dose changes). Still early data. EV (n=22, 34% pCR, also with neoadjuvant tox). R3s with EVP

interest in HER 2 & 3 expression in urothelial cancer due to new ADCs. Exploratory analysis from R3 LAMB trial shows ~50% of tumors are HER2 and HER3 +ve. HER2 maybe associated with short PFS. Disitimab vedotin in R3 in 1st line UC, HER3 ADCs awaited in UC @b_szabados @IBCN23